Thursday, July 20, 2017 1:02:35 PM
Sexual health is a major topic of discussion and research because it affects both males and females. Sexual health issues, sometimes termed sexual dysfunction, may be the result of organic issues, psychological issues or a combination of both.
Examples of organic issues include vascular diseases, such as those associated with hypertension or diabetes mellitus, prescription medication, and/or by psychiatric disease such as depression.
Examples of psychological factors include fear, performance anxiety, and interpersonal conflict. Sexual health issues and sexual dysfunction issues, in particular, may impair sexual performance, diminish self-esteem and disrupt personal relationships thereby inducing personal distress.
Male sexual health issues or dysfunction issues include male erectile dysfunction, ejaculatory disorders, such as premature ejaculation, anorgasmia (inability to achieve orgasm) and desire disorders such as hypoactive sexual desire disorder (lack of interest in sex).
Female sexual health issues or dysfunction issues include genitopelvic pain/penetration disorders, sexual interest/arousal disorders, and female orgasmic disorders.
Robert Goldfarb, COO of INTIVA BioPharma, stated, “Due to the scope of male and female health issues, there is a need for improvements in the treatments.” He further stated, “For both men and women anecdotal evidence suggests benefits in using cannabinoids and/or terpenes for improving sexual health. We’re hopeful that our pre-clinical and clinical pathway will lead to one or more medicines that improve conditions affecting male and female sexual health.”
INTIVA BioPharma has assembled a team of experienced professionals in pharmaceutical development and regulatory compliance for its drug development activities
Recent NXEN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 11:19:50 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 11:04:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 08:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 08:02:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 10:06:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2023 09:41:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2023 07:35:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM